Survodutide Phase 2 trial (NCT04771273)
Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 295
- actual
- Start
- 27 Apr 2021 (actual)
- Primary completion
- 9 Nov 2023 (actual)
- Sponsor
- Boehringer Ingelheim
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Survodutide 2.4 mg - planned maintenance treatment | Experimental | Drug: Survodutide | Not stated |
| Survodutide 4.8 mg - planned maintenance treatment | Experimental | Drug: Survodutide | Not stated |
| Survodutide 6.0 mg - planned maintenance treatment | Experimental | Drug: Survodutide | Not stated |
| Placebo - planned maintenance treatment | Placebo comparator | Drug: Placebo | Not stated |
Primary endpoint
| Measure | Time frame |
|---|---|
| Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment | At baseline and at 48 weeks. |
| Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance Treatment | At baseline and after 48 weeks of treatment. |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Actual Maintenance Treatment | At baseline and after 48 weeks. |
| Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Planned Maintenance Treatment | At baseline and at 48 weeks. |
| Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment | MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported. |
| Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment | MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported. |
| Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment | MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported. |
| Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment | MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported. |
| Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment | At baseline and after 48 weeks of treatment. |
| Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment | At baseline and after 48 weeks of treatment. |
| Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment | At baseline and 48 weeks of treatment. |
| Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment | At baseline and 48 weeks of treatment. |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04771273.
Survodutide in biopsy-confirmed MASH with fibrosis
Adults with biopsy-confirmed MASH and fibrosis stage F1 to F3 were randomised 1:1:1:1 to survodutide 2.4, 4.8 or 6.0 mg or placebo for 48 weeks.[2]
MASH improved without worsening of fibrosis in 47%, 62% and 43% of the three survodutide groups against 14% on placebo.[2]
Liver fat fell by at least 30% in 63%, 67% and 57% of survodutide participants and 14% on placebo; fibrosis improved by one stage in 34%, 36%, 34% and 22%.[2]
Nausea (66% vs. 23%), diarrhea (49% vs. 23%) and vomiting (41% vs. 4%) were more frequent with survodutide, with serious events at 8% against 7%.[2]
Sources
- 1Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026
Found an error? Report a correction.